Clinical trials: Moderate to Severe Papulopustular Rosacea
Papulopustular Rosacea
Safety and Efficacy of Rifaximin in Patients With Papulopustular Rosacea and Positive Lactulose Breath Test
Preliminary evidence suggests that treatment with rifaximin may be beneficial in patients with papulopustular rosacea. The present clinical trial is aimed to investigate the safety and efficacy of oral rifaximin delayed release…
- Trial name
- NCT03864978
- Testing
- Rifaximin delayed release 400 mg tablet
- Where
- 12 sites in Italy
- Volunteers
- 236 people
- Sponsor
- Alfasigma S.p.A.
Moderate to Severe Papulopustular Rosacea
Open Label Phase 2 Feasibility Study of BPX-04 Topical Minocycline Gel in Rosacea
An open label feasibility study using BPX-04 topical minocycline gel in papulopustular rosacea.
- Trial name
- NCT03050086
- Testing
- BPX-04 1% minocycline topical gel, BPX-04 2% minocycline topical gel, BPX-04 vehicle topical gel
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- BioPharmX, Inc.
Papulopustular Rosacea
Safety, Efficacy and Pharmacokinetics of Rifaximin in Patients With Moderate-to-severe Papulopustular Rosacea
Rosacea is a common chronic inflammatory relapsing-remitting skin condition almost exclusively affecting the central area of the face and the eyes.
- Trial name
- NCT05150587
- Testing
- Rifaximin
- Where
- 38 sites in United States
- Volunteers
- 216 people
- Sponsor
- Alfasigma S.p.A.
Moderate to Severe Papulopustular Rosacea
Clinical Endpoint Study of Ivermectin 1% Cream
A randomized, double-blind, placebo-controlled, parallel-design, multiple-site clinical study to evaluate the therapeutic equivalence and safety of ivermectin cream 1% (Actavis Laboratories UT, Inc.) to SoolantraTM (ivermectin)…
- Trial name
- NCT02840461
- Testing
- Ivermectin Cream, 1%
- Where
- United States
- Volunteers
- 630 people
- Sponsor
- Actavis Inc.
Papulopustular Rosacea
A Study to Evaluate the Long-Term Safety of Topical Administration of FMX103 in the Treatment of Moderate to Severe Papulopustular Rosacea
The primary objective is to show that open-label extended treatment with FMX103 1.5%, for up to an additional 40 weeks, is safe and well tolerated.
- Trial name
- NCT03276936
- Testing
- FMX103 1.5%
- Where
- 79 sites in United States
- Volunteers
- 504 people
- Sponsor
- Vyne Therapeutics Inc.